Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis-a serological evaluation

Liver International

Volumn 33, Issue 3, 2013, Pages 439-447

  Leeming, Diana J ^a   Byrjalsen, Inger ^a   Jiménez, Wladimiro ^b   Christiansen, Claus ^a   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Biochemical markers; CCl4 model; Collagens; Connective tissue; Protoglycans

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BIGLYCAN; BIOCHEMICAL MARKER; CARBON TETRACHLORIDE; CITRULLINATED VIMENTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGEN TYPE 6; CREATININE; LACTATE DEHYDROGENASE; MATRIX METALLOPROTEINASE; POTASSIUM; PROCOLLAGEN; PROCOLLAGEN TYPE 3; PROCOLLAGEN TYPE 4; PROCOLLAGEN TYPE 5; SODIUM; UNCLASSIFIED DRUG; VIMENTIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD OSMOLARITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; EXTRACELLULAR MATRIX; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FIBROSIS; MALE; NONHUMAN; POTASSIUM BLOOD LEVEL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; RAT; SEROLOGY; SODIUM BLOOD LEVEL;

ALANINE TRANSAMINASE; ANIMALS; BIGLYCAN; BIOLOGICAL MARKERS; CARBON TETRACHLORIDE; COLLAGEN TYPE I; CREATININE; EXTRACELLULAR MATRIX; L-LACTATE DEHYDROGENASE; LINEAR MODELS; LIVER CIRRHOSIS; MALE; OSMOLAR CONCENTRATION; PEPTIDE MAPPING; POTASSIUM; RATS; RATS, WISTAR; SERUM ALBUMIN; SODIUM; VIMENTIN;

EID: 84873746994     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12044     Document Type: Article

References (41)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-51.
3. Talwalkar JA. Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis. Liver Int 2008; 28: 761-3.
4. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med 2007; 11: 1031-51.
5. Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis 2008; 12: 883-900.
6. Parkes J, Guha IN, Roderick P, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011; 18: 23-31.
7. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6.
8. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 11: 91.
9. Yilmaz Y, Yonal O, Kurt R, et al. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon 2011; 11: 103-6.
10. Crespo G, Fernandez-Varo G, Marino Z, et al. ARFI, Fibroscan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol 2012; 57: 281-7.
11. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99.
12. Zhen EY, Brittain IJ, Laska DA, et al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008; 58: 2420-31.
13. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38(Suppl 1): S38-53.
14. Reichenbach V, Ros J, Fernandez-Varo G, et al. Prevention of fibrosis progression in CCl4-treated rats: role of the hepatic endocannabinoid and apelin systems. J Pharmacol Exp Ther 2012; 340: 629-37.
15. Kirimlioglu H, Kirimlioglu V, Yilmaz S. Expression of matrix metalloproteinases 2 and 9 in donor liver, cirrhotic liver, and acute rejection after human liver transplantation. Transplant Proc 2008; 40: 3574-7.
16. Gieling RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1324-31.
17. Karsdal MA, Henriksen K, Leeming DJ, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009; 14: 181-202.
18. Karsdal MA, Henriksen K, Leeming DJ, et al. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers - are they the cause or the consequence of the disease?. Clin Chem 2010; 43: 793-804.
19. Segovia-Silvestre T, Reichenbach V, Fernandez-Varo G, et al. Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair 2011; 4: 19.
20. Clarià J, Jimenez W. Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats. In: Arroyo V, Schrier RW, Rodés J, Ginès P, eds. The Liver and the Kidney. Boston: Blackwell Science, 1999; 379-96.
21. Clária J, Jiménez W. Experimental Models of Cirrhosis and Ascites. Ascites and Renal Dysfunction., 2nd edn. Oxford UK: Blackwell Publishing ltd, 2005.
22. Munoz-Luque J, Ros J, Fernandez-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008; 324: 475-83.
23. Leeming DJ, He Y, Veidal SS, et al. A novel marker for assessment of liver extracellular matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011; 16: 616-28.
24. Barascuk N, Veidal SS, Larsen L, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 2010; 43: 899-904.
25. Veidal SS, Karsdal MA, Nawrocki A, et al. Assessing proteolytic degradation of the basement membrane: A fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis & Tissue Repair 2011; 5: 22.
26. Veidal SS, Karsdal MA, Vassiliadis E, et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis-identification and validation of a novel biochemical marker. PlosONE 2011; 6: e24753.
27. Vassiliadis E, Zhang C, Henriksen K, et al. Citrullination and MMP degradation of vimentin, a key event in fibrosis and tissue destruction. Am J Transl Res 2012; 4: 403-14.
28. Leeming DJ, Nielsen MJ, Dai Y, et al. An Enzyme-linked Immunosorbent Serum Assay (ELISA) specific for the 7S domain of Collagen Type IV (PIVNP 7S) -a marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatology Research 2012; 42: 482-93.
29. Vassiliadis E, Veidal SS, Simonsen H, et al. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers 2011; 16: 426-33.
30. Leeming D, He Y, Veidal S, et al. A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011; 16: 616-28.
31. Veidal SS, Karsdal MA, Nawrocki A, et al. Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair 2011; 4: 22.
32. Veidal SS, Karsdal MA, Vassiliadis E, et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis-identification and validation of a novel biochemical marker assay. PLoS ONE 2011; 6: e24753.
33. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007; 381: 107-13.
34. Bentsen KD, Horn T, Risteli J, et al. Serum aminoterminal type III procollagen peptide and the 7S domain of type IV collagen in patients with alcohol abuse. Relation to ultrastructural fibrosis in the acinar zone 3 and to serum hyaluronan. Liver 1987; 7: 339-46.
35. Cho JJ, Lee YS. Enzyme-linked immunosorbent assay for serum procollagen type III peptide in rats with hepatic fibrosis. J Vet Med Sci 1998; 60: 1213-20.
36. Farkkila M, Rautiainen H, Karkkainen P, et al. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int 2008; 28: 787-97.
37. Lieber CS, Weiss DG, Paronetto F. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res 2008; 32: 1031-9.
38. Stickel F, Urbaschek R, Schuppan D, et al. Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig Dis Sci 2001; 46: 2025-32.
39. de Meijer VE, Sverdlov DY, Popov Y, et al. Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS ONE 2010;5:e11256.
40. Greenwel P, Rojkind M. Accelerated development of liver fibrosis in CCl4-treated rats by the weekly induction of acute phase response episodes: upregulation of alpha1(I) procollagen and tissue inhibitor of metalloproteinase-1 mRNAs. Biochim Biophys Acta 1997; 1361: 177-84.
41. Ogata I, Auster AS, Matsui A, et al. Up-regulation of type I procollagen C-proteinase enhancer protein messenger RNA in rats with CCl4-induced liver fibrosis. Hepatology 1997; 26: 611-7.